$Longeveron (LGVN.US)$ [Share Link: Longeveron Reports Posit...

The Phase 2B trial for the CLEAR MIND study, which evaluates Lomecel-B for mild Alzheimer's disease, is anticipated to start following a meeting with the FDA before the end of 2024. This meeting aims to outline the future clinical and regulatory strategy for Lomecel-B, based on the positive results from the Phase 2A trial. Specific timelines for initiating the Phase 2B trial will depend on the outcomes of this meeting and subsequent preparations by Longeveron.

strangely why stock price still goes down??